The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Cancer cells frequently exploit the IGF signaling, a fundamental pathway mediating development, cell growth, and survival. As a consequence, several components of the IGF signaling are deregulated in cancer and sustain cancer progression. However, specific targeting of IGF-IR in humans has resulted efficacious only in small subsets of cancers, making researches wondering whether IGF system targeting is still worth pursuing in the clinical setting. Although no definite answer is yet available, it has become increasingly clear that other components of the IGF signaling pathway, such as IR-A, may substitute for the lack of IGF-IR, and induce cancer resistance and/or clonal selection. Moreover, accumulating evidence now indicates that IGF signaling is a central player in the induction/maintenance of epithelial mesenchymal transition (EMT) and cell stemness, two strictly related programs, which play a key role in metastatic spread and resistance to cancer treatments. Here we review the evidences indicating that IGF signaling enhances the expression of transcription factors implicated in the EMT program and has extensive cross-talk with specific pathways involved in cell pluripotency and stemness maintenance. In turn, EMT and cell stemness activate positive feed-back mechanisms causing up-regulation of various IGF signaling components. These findings may have novel translational implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2023) · doi:10.1126/science · Cited by 6,063
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666 · cited 1×
“The tightly regulated activation of Wnt/β-catenin signaling, as well as β-catenin expression and localization may be subverted in a variety of human cancers, thus inducing an imbalance between long-term renewal and differentiation program (12, 101), which favors CSCs expansion (100).”
BackgroundPolakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183 · cited 1×
“Indeed, the apc gene, encoding the APC protein, is silenced in over 80% of human colon cancer (106).”
BackgroundSnail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“Initially identified as an enzyme involved in the regulation of glycogen synthesis in response to insulin, GSK3β is known to play a key role in the canonical Wnt signaling by phosphorylating β-catenin and inducing its proteasomal targeting and degradation (see below) (41, 42).”
BackgroundWNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · cited 1×
“Besides being activated by hypoxia, HIFs are also activated by several growth factors, including IGFs (86) through the PI3K/Akt/mTOR pathway (87).”
BackgroundSuppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 1×
“Cell reprograming is more efficient when p53 is inactivated (76), indicating that p53 plays also a key role in the regulation of stemness.”
BackgroundBrogiolo, W., Stocker, H., Ikeya, T., Rintelen, F., Fernandez, R., & Hafen, E. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00068-9 · Cited by 1,255
Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009) · Stem Cells · doi:10.1002/stem.154 · Cited by 655
Desbois-Mouthon, C., Cadoret, A., Blivet-Van Eggelpoël, M.-J., Bertrand, F., Cherqui, G., Perret, C., & Capeau, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204064 · Cited by 321
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296
McDevitt, T. C., Laflamme, M. A., & Murry, C. E. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.007 · Cited by 183
Cited by
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Self-citationLipid rafts as major platforms for signaling regulation in cancer
Mollinedo, F., & Gajate, C. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.10.003 · Cited by 308
Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., et al. (2018) · Hepatology · doi:10.1002/hep.29660 · Cited by 160
Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk
Jin, L., Shen, F., Weinfeld, M., & Sergi, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00727 · Cited by 123
Dietary patterns and risk of hepatocellular carcinoma among U.S. Men and women
Ma, Y., Yang, W., Simon, T. G., Smith‐Warner, S. A., Fung, T. T., Sui, J., Chong, D., VoPham, T., Meyerhardt, J. A., Wen, D., et al. (2019) · Hepatology · doi:10.1002/hep.30362 · Cited by 103
“(44,45) High IGF-1 levels were reported to contribute to the development of several cancers, including HCC in experimental studies.(46,47) Similarly, low intake of SSB and/ or fruit juice and low-sodium diets are included in AHEI-2010 and DASH scores, whereas AMED score did not include fruit juice intake or SSB.”
Background
Metadata
- Authors
- Malaguarnera, R., & Belfiore, A.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 5
- Pages
- 10-10
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2023059800
- Cited by
- 143
- References
- 16
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.